Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.02) earnings per share for the quarter, Zacks reports.
Enzon Pharmaceuticals Price Performance
ENZN opened at $0.06 on Wednesday. The firm has a market cap of $4.65 million, a P/E ratio of -1.25 and a beta of 0.20. Enzon Pharmaceuticals has a 52 week low of $0.03 and a 52 week high of $0.13. The business has a fifty day simple moving average of $0.06 and a 200-day simple moving average of $0.06.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Read More
- Five stocks we like better than Enzon Pharmaceuticals
- New Copper-Rich “Kraken” Zone Discovered
- Elon Warns “America Is Broke”. Trump’s Plan Inside.
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
